Reports Q2 revenue $31.1M, consensus $28.31M. “We delivered an excellent second quarter, with $31.1 million in net sales, up 37% year-over-year, and $3.6 million in net income,” said Niagen Bioscience (NAGE) CEO Rob Fried. “As the pioneers of this blossoming NAD+ market, we continue to invest in the future while maintaining our focus on profitable growth.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
- Niagen Bioscience: Promising Clinical Results and Strategic IP Acquisitions Drive Buy Rating
- Niagen Bioscience Subsidiary Signs Supply Agreement
- Niagen Bioscience licenses potential Parkinson’s therapy
- Niagen Bioscience Approves Equity Plan Amendment
- Niagen Bioscience price target raised to $16 from $13 at Canaccord